Research units of pediatric psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: One-year follow-up

L. Eugene Arnold, Michael G. Aman, Xiaobai Li, Eric Butter, Kristina Humphries, Lawrence Scahill, Luc Lecavalier, Christopher J. McDougle, Naomi Swiezy, Benjamin Handen, Krystina Wilson, Kimberly A. Stigler

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p =.006, d = 0.34), irritability (p =.01, d = 0.48), and hyperactivity/noncompliance (p =.04, d = 0.55) with a lower medication dose. Method: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. Results: Eighty-seven of 124 families (70.2%) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53% of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39% of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. Conclusions: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.

Original languageEnglish
Pages (from-to)1173-1184
Number of pages12
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume51
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Psychopharmacology
Autistic Disorder
Randomized Controlled Trials
Pediatrics
Research
Therapeutics
Antipsychotic Agents
Social Adjustment
Risperidone
Medication Adherence
Telephone

Keywords

  • antipsychotic
  • autism
  • clinical trial
  • follow-up
  • parent training

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Research units of pediatric psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication : One-year follow-up. / Arnold, L. Eugene; Aman, Michael G.; Li, Xiaobai; Butter, Eric; Humphries, Kristina; Scahill, Lawrence; Lecavalier, Luc; McDougle, Christopher J.; Swiezy, Naomi; Handen, Benjamin; Wilson, Krystina; Stigler, Kimberly A.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 51, No. 11, 11.2012, p. 1173-1184.

Research output: Contribution to journalArticle

Arnold, L. Eugene ; Aman, Michael G. ; Li, Xiaobai ; Butter, Eric ; Humphries, Kristina ; Scahill, Lawrence ; Lecavalier, Luc ; McDougle, Christopher J. ; Swiezy, Naomi ; Handen, Benjamin ; Wilson, Krystina ; Stigler, Kimberly A. / Research units of pediatric psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication : One-year follow-up. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2012 ; Vol. 51, No. 11. pp. 1173-1184.
@article{f765671c100f42f2af0555dfd22614b8,
title = "Research units of pediatric psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: One-year follow-up",
abstract = "Objective: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p =.006, d = 0.34), irritability (p =.01, d = 0.48), and hyperactivity/noncompliance (p =.04, d = 0.55) with a lower medication dose. Method: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. Results: Eighty-seven of 124 families (70.2{\%}) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53{\%} of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39{\%} of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. Conclusions: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.",
keywords = "antipsychotic, autism, clinical trial, follow-up, parent training",
author = "Arnold, {L. Eugene} and Aman, {Michael G.} and Xiaobai Li and Eric Butter and Kristina Humphries and Lawrence Scahill and Luc Lecavalier and McDougle, {Christopher J.} and Naomi Swiezy and Benjamin Handen and Krystina Wilson and Stigler, {Kimberly A.}",
year = "2012",
month = "11",
doi = "10.1016/j.jaac.2012.08.028",
language = "English",
volume = "51",
pages = "1173--1184",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Research units of pediatric psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication

T2 - One-year follow-up

AU - Arnold, L. Eugene

AU - Aman, Michael G.

AU - Li, Xiaobai

AU - Butter, Eric

AU - Humphries, Kristina

AU - Scahill, Lawrence

AU - Lecavalier, Luc

AU - McDougle, Christopher J.

AU - Swiezy, Naomi

AU - Handen, Benjamin

AU - Wilson, Krystina

AU - Stigler, Kimberly A.

PY - 2012/11

Y1 - 2012/11

N2 - Objective: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p =.006, d = 0.34), irritability (p =.01, d = 0.48), and hyperactivity/noncompliance (p =.04, d = 0.55) with a lower medication dose. Method: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. Results: Eighty-seven of 124 families (70.2%) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53% of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39% of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. Conclusions: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.

AB - Objective: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p =.006, d = 0.34), irritability (p =.01, d = 0.48), and hyperactivity/noncompliance (p =.04, d = 0.55) with a lower medication dose. Method: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. Results: Eighty-seven of 124 families (70.2%) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53% of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39% of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. Conclusions: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.

KW - antipsychotic

KW - autism

KW - clinical trial

KW - follow-up

KW - parent training

UR - http://www.scopus.com/inward/record.url?scp=84867897955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867897955&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2012.08.028

DO - 10.1016/j.jaac.2012.08.028

M3 - Article

C2 - 23101743

AN - SCOPUS:84867897955

VL - 51

SP - 1173

EP - 1184

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 11

ER -